Across TCGA pan-cancer cohorts, TNFAIP2 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of TNFAIP2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where TNFAIP2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TNFAIP2 is over-expressed in tumor, although a few such as COAD and HNSC show the opposite, repressed pattern.

CCRCC, COAD, and PDAC are the cancer types where TNFAIP2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TNFAIP2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	All	+0.467	<.001	9	view →
COAD	Male	III,IV	−0.384	<.001	9	view →
PDAC	All	All	+0.347	<.001	6	view →
HNSC	All	III,IV	−0.186	.013	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: TNFAIP2 RNA expression & survival · all TNFAIP2 data types